Medicines

AstraZeneca markets the following medicines in Switzerland:

You can find the information for healthcare professionals and patient information documents here: www.swissmedicinfo.ch. 

Patient safety

Please report side effects and adverse events on our reporting platform: (web form)
Or by email/phone: patientsafety.ch@astrazeneca.com / +41 41 725 77 77
Report product quality by e-mail/telephone: 
Swiss-QA@astrazeneca.com / +41 41 725 75 75

Medical enquiries

medinfo.ch@astrazeneca.com / +41 41 725 77 77

Research

Research and development lie at the heart of AstraZeneca. In 2023, we invested 10.9 billion US Dollars (24% of our total revenue) in research and development. According to the magazine Fierce Biotech, AstraZeneca is the fifth biggest investor in research and development as a proportion of its sales.

By 2030, AstraZeneca is planning to bring 15 new medicines to market. In Switzerland, we are planning to launch over 35 new therapies with the potential to improve current treatment standards on to the market by 2026. AstraZeneca has one of the most promising ‘pipelines’ in the industry.

Publication of clinical trial results

Development

We relentlessly drive our research and development in search of new insights and the next breakthrough. On average, it takes twelve years to develop a new medicine. The chances of success are around 10 percent, because unsatisfactory efficacy or severe side effects are often only identified in costly clinical trials.

Out of 10,000 compounds developed, only 20 make it to the preclinical phase, and of these, only ten will in turn make it to the clinical phase. Of these, only one drug will ultimately make it to market.

You can find out more about research and development here.
How is a new Meditation created

Find out more about the long journey of a medicine in the Interpharma video.

Our pipeline.

Learn more about the development of our portfolio.